Results 171 to 180 of about 31,601 (273)

The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process

, 2011
Jonathan Stroud
openalex   +1 more source

How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity

, 2018
Beate Beyer, Nicole Walch, Alois Jungbauer, Nico Lingg   +3 more
openalex   +1 more source

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. [PDF]

J Clin Med
Shehab M, Almajdi A, Abdullah I, Alrashed F.   +3 more
europepmc   +1 more source

ABS0695 SEX DIFFERENCES ASSOCIATED WITH OVERALL TOLERANCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR, A POST-HOC ANALYSIS FROM THE YU-MATTER STUDY

H. Marotte, Guillaume Bouguen, Azeddine Dellal, L. Foulley, C. Habauzit, Salim Benkhalifa, Laure Gossec   +6 more
openalex   +1 more source

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]

Health Aff Sch
Beinfeld MT, Ghule P, LaMountain F, Wong W, Ko S, Chambers JD.   +5 more
europepmc   +1 more source

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience

, 2019
Wieland D Müskens, Sanne A A Rongen-van Dartel, Eddy Adang, Piet L. C. M. van Riel   +3 more
openalex   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study. [PDF]

Biologics
Pápista M, Resál T, Bacsur P, Kata D, Farkas B, Bálint A, Fábián A, Bor R, Ivány E, Szepes Z, Farkas K, Juhász Z, Buzás N, Molnár T.   +13 more
europepmc   +1 more source

AB043. Biosimilar medicines: a cross-sectional study on hospital pharmacists’ perceived confidence and barriers to promote prescribing among clinicians in Malaysia

, 2021
Noraisyah Mohd Sani, Zoriah Aziz, Adeeba Kamarulzaman   +2 more
openalex   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source